← Back to 52-Week Low Lens

MEDLEY INC

────────────────────────
1. Company Overview
────────────────────────

Medley is a Japanese healthtech company built around two businesses: a healthcare-focused hiring marketplace and workflow software for clinics, pharmacies, and dental offices. Its best-known product is JobMedley, a recruitment platform for medical and nursing-care employers. Its second leg is the Medical Platform business, led by CLINICS for online and in-person practice support, plus Pharms for pharmacies and Dentis for dental clinics.

At a share price of ¥1,747 on 19 March 2026, Medley’s market cap is about ¥52.5 billion. Using FY2025 year-end balance sheet figures, cash was about ¥8.6 billion and total debt about ¥16.1 billion, so net debt was roughly ¥7.5 billion and enterprise value about ¥60.0 billion. FY2025 EBITDA was ¥4.8 billion, implying EV/EBITDA of about 12.5x. Operating cash flow was ¥3.5 billion. Reported capex has been low, roughly ¥0.2–0.3 billion a year. Using FY2025 EBITDA of ¥4.8 billion, less estimated sustaining capex of roughly ¥0.25 billion and a normal working-capital need of roughly ¥0.7–1.0 billion in a growth year, operating owner earnings look to be around ¥3.6–3.9 billion. That estimate excludes no add-back for stock compensation; I am treating SBC as a real cost, but public snippets do not isolate the exact number. On that basis, the stock trades at roughly a 6.9–7.4% operating owner-earnings yield on equity.

The economic core is still the HR Platform business. In Q4 FY2025, HR Platform EBITDA margin was 40%, versus only 4% for the Medical Platform. That tells you where the profits come from: JobMedley and related hiring services fund the group; clinic and pharmacy software is strategically important but still much less profitable.

Historically, this has been a good business for two reasons. First, JobMedley operates in labor markets with chronic shortages: nursing care, medical assistants, pharmacists, and other healthcare roles. That creates steady employer demand. Second, the model is asset-light. Revenue scaled from ¥14.2 billion in 2022 to ¥20.5 billion in 2023, ¥29.3 billion in 2024, and ¥36.8 billion in 2025, while capex stayed small. High growth with low capital intensity is what made Medley attractive. The question now is whether that engine has merely slowed, or whether it has been impaired.

────────────────────────
2. Why the Stock Is Near a 52-Week Low
────────────────────────

The stock is down about 53% from its 52-week high of ¥3,720 and is only slightly above its 52-week low of ¥1,725. That is not a normal pullback. The market is saying that either growth quality deteriorated, or the old margin structure is no longer trustworthy.

The plain-English reason is this: Medley kept growing revenue, but the market stopped believing that the growth is as valuable as before. Management said HR Platform sales growth decelerated through H1 FY2025 because of weaker market conditions from mid-FY2024 and FY2025 regulatory changes regarding continuous service allowance. At the same time, operating profit kept falling despite higher sales, and the balance sheet moved from net cash to net debt after acquisitions. Investors now worry that the high-margin hiring engine is maturing just as Medley becomes more acquisition-heavy and more dependent on lower-margin software.

That combination explains the derating. The market is not reacting to collapsing revenue. It is reacting to lower confidence in future incremental returns.

────────────────────────
3. What the Market Is Currently Pricing In
────────────────────────

(a) One-time / cyclical / sentiment-driven factors

The market is pricing in a classic growth-stock de-rating: slower near-term HR growth, lower forecast confidence, and weaker optics from falling operating profit. It is also pricing in temporary noise from acquisition-related amortization and integration costs, which depress accounting profit more than cash generation.

(b) Medium-term business headwinds

The market is pricing in a lower-growth HR Platform over the next several years, not just one soft half. That includes weaker employer demand, less favorable monetization, and some regulatory friction in healthcare hiring. It is also pricing in persistent group-level margin dilution because the Medical Platform is still far less profitable than HR. Finally, it is pricing in higher financial risk after the balance sheet moved from roughly ¥3.8 billion net cash at end-FY2024 to roughly ¥7.5 billion net debt at end-FY2025.

(c) Potential long-term structural threats

The deepest fear is that JobMedley’s core mechanism may be losing edge: employers may shift more hiring to cheaper channels, direct sourcing, or large generalist platforms, reducing Medley’s pricing power and conversion economics. A second structural fear is that clinic software becomes a lower-moat category as EMR/practice-management tools proliferate and AI reduces product differentiation. A third is that Medley becomes a serial acquirer without earning durable returns on acquired goodwill, turning what was once a clean marketplace compounder into a more fragile roll-up.

────────────────────────
4. Reality Check vs Market Narrative
────────────────────────

The “growth is over” narrative is too extreme. Revenue has not stalled; it has compounded hard for four years: ¥14.2 billion in 2022, ¥20.5 billion in 2023, ¥29.3 billion in 2024, and ¥36.8 billion in 2025. That is a 2.6x increase in three years. Customer contracts also kept rising. Management reported 408 thousand customer contracts in FY2024 and 448 thousand in FY2025, up 9.9%. The business has clearly slowed from hypergrowth, but the customer base is still expanding.

The “profitability is broken” narrative is only half right. EBITDA rose from roughly ¥3.4 billion in 2023 to ¥4.1 billion in 2024 and ¥4.8 billion in 2025. Q4 FY2025 EBITDA margin recovered to 13%, up 5 points year on year. But operating profit did fall: about ¥2.67 billion in 2023, ¥2.33 billion in 2024, and ¥2.15 billion in 2025. So the cash-profit engine is not broken, but accounting profit quality has weakened because of amortization, mix shift, and cost growth.

The “cash flow is deteriorating” narrative is not supported by the latest numbers. Operating cash flow was about ¥3.87 billion in 2023, dipped to ¥2.45 billion in 2024, then recovered to ¥3.49 billion in 2025. With capex still minimal, Medley remains cash generative. This matters because a business near a 52-week low with still-positive and sizable operating cash flow is not in distress; it is in a confidence problem.

The “balance sheet is no longer pristine” narrative is true. This is the cleanest negative datapoint. Cash and short-term investments fell from about ¥19.0 billion at end-FY2024 to about ¥8.6 billion at end-FY2025, while total debt rose from about ¥15.2 billion to about ¥16.1 billion. Quartr’s summary also notes goodwill-to-equity rose to 1.54x. That is real fragility. It does not break the business model, but it does reduce room for error.

The “Medical Platform is still low quality” narrative is directionally right but incomplete. Medical Platform posted its first full year in the black in FY2024, and Q4 FY2025 EBITDA margin was 4%. That is still weak relative to HR, but it is not a money pit anymore. The market seems to be treating it as a structurally weak business; the data says it is at least improving.

────────────────────────
5. Structural vs Non-Structural Diagnosis
────────────────────────

First structural concern: possible weakening of the HR Platform’s customer acquisition and monetization mechanism. The damaged mechanism would be the hiring marketplace flywheel: employer demand, applicant liquidity, and take-rate economics. Based on the available data, this does not yet look like essence damage. Customer contracts still rose from 408 thousand to 448 thousand in FY2025, and revenue still grew 26% in 2025. The mechanism slowed, but it is still functioning. This looks reversible within three years if regulation is absorbed and labor shortages remain acute. Classification: (c) Not truly structural.

Second structural concern: acquisition-driven balance-sheet fragility. The damaged mechanism here is not product demand but financial resilience and capital allocation flexibility. Moving from net cash to roughly ¥7.5 billion net debt in one year, while goodwill-to-equity rises to 1.54x, makes the business more vulnerable to execution mistakes. This is reversible within three years because the business still generates material operating cash flow and capex is low. But it is real structural risk because it changes the company’s tolerance for error. Classification: (b) Structural but survivable.

Third structural concern: commoditization risk in the Medical Platform. The damaged mechanism would be pricing power and switching-cost accumulation in clinic and pharmacy workflow software. If CLINICS, Pharms, and Dentis end up as replaceable tools rather than embedded workflow systems, Medley may never earn attractive returns on that segment. This is only partially reversible within three years. Once software categories commoditize, it is hard to rebuild pricing power quickly. Still, Medical Platform is now profitable and embedded into regulated healthcare workflows, which slows commoditization. Classification: (b) Structural but survivable.

What is notably absent is clear evidence that the core HR Platform moat has already broken. The data shows deceleration, not disintermediation.

────────────────────────
6. Time-as-a-Moat Test
────────────────────────

With Medley’s current market cap in cash, you could build software and spend aggressively on sales. You could not realistically rebuild Medley’s position in two years. The main blocker would be distribution into a fragmented, trust-based healthcare customer base. Healthcare employers and clinics do not adopt workflow or hiring tools like ordinary SMB software buyers. Category trust, regulatory familiarity, and vertical sales execution matter.

In five years, you could probably build a credible competitor in one leg of the business. You could build a healthcare recruitment platform, or you could build clinic software. Doing both at meaningful scale, with cross-sell potential and embedded relationships, would still be difficult. What would block you is not code. It is the installed base, brand inside the healthcare labor market, and the operational knowledge of how Japanese medical and nursing-care institutions buy.

In ten years, yes, a determined and well-funded competitor could likely rebuild something comparable. But even then, time remains a moat because the business sits on accumulated employer relationships, product integrations, workflow habits, and sector trust. Medley’s moat is not deep enough to be permanent, but it is deep enough that replication is slow and costly.

────────────────────────
7. Moat & Mispricing Score
────────────────────────

Score: 7/10.

The market is getting one important thing wrong: it is treating HR Platform deceleration as if the core hiring flywheel were already impaired. The numbers do not show that. Revenue rose from ¥20.5 billion in 2023 to ¥29.3 billion in 2024 and ¥36.8 billion in 2025, and customer contracts rose from 408 thousand to 448 thousand in 2025. What the market is getting right is that Medley is no longer a pristine marketplace: net debt is now about ¥7.5 billion and goodwill is high. At today’s ¥52.5 billion equity value, the stock implies an operating owner-earnings yield of roughly 6.9–7.4%; if the required yield for a still-growing, still-moated HR asset is closer to 6.0–6.5%, the equity looks undervalued by roughly ¥8–12 billion. That is a moderate mispricing, not a screaming one.

────────────────────────
8. Final Sanity Check
────────────────────────

No.

If Medley disappeared tomorrow, Japan would rebuild the functions: healthcare hiring marketplaces and clinic workflow software are too useful not to exist. But the world would probably not rebuild Medley in exactly the same integrated form. The hiring marketplace and the clinic software stack would likely re-emerge as separate businesses or under different owners. That means Medley is useful and defensible, but not inevitable.

CoffeeAnd — 52-week low lens